KineMed Inks Deal with Amgen to Study Brain Proteins Linked to Neurodegenerative Disease | GenomeWeb

NEW YORK (GenomeWeb News) – KineMed said today that it has entered an agreement with Amgen to apply its mass spec-based Dynamic Proteomics platform to the study of brain protein homeostasis in neurodegenerative disease.

Amgen will use the data generated by the platform to track synthesis and clearance rates of pathogenic brain proteins that drive neurodegeneration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.